Thymosin alpha-1: Research, Studies & Structure

What is Thymosin alpha-1?

Thymosin alpha-1, also called thymalfasin, is investigated for immune-related effects. The clinical value of immune modulation depends on the disease and endpoint.

Biological role or research focus

Immune modulation.

Findings in severely ill patients must not be generalized to “boosting immunity” in healthy people.

Role reference: The efficacy and safety of thymosin Î±1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. ↗

Names you may encounter

thymosin alpha 1 · TA-1 · thymalfasin

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity: Immunomodulatory peptide
Main research area: Disease-specific immune research
Evidence featured: Human phase 3 trial
Source check: October 4, 2026

Source: The efficacy and safety of thymosin Î±1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. ↗

Molecular structure

⤢ Enlarge 2D

2D molecular structureThe cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.PubChem · CID 16130571 ↗

Mechanism & research rationale

Research aims to alter immune responses rather than simply increase them. A meaningful test asks whether that intervention improves a patient outcome such as survival.

Source: The efficacy and safety of thymosin Î±1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. ↗

Research context & status

The selected phase 3 sepsis trial did not demonstrate a mortality benefit. It should not be used as support for an undefined “immune boost” in healthy people.

Source: The efficacy and safety of thymosin Î±1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. ↗

What does the evidence show?

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human phase 3 trial · 2025

TESTS

The efficacy and safety of thymosin Î±1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.

Population / model: 1,106 adults with sepsis randomized across 22 centers in China.
Study design: Blinded placebo-controlled trial; 1,089 participants in the modified intention-to-treat analysis.
Main finding: Twenty-eight-day mortality was 23.4% versus 24.1%; hazard ratio 0.99 (95% CI 0.77–1.27). No clear mortality benefit was demonstrated.
Limits & context: A large negative overall result should not be replaced by favorable subgroup headlines. Sepsis treatment also differs substantially from immune-enhancement claims in healthy people.

Read PubMed abstract ↗Publisher paper ↗Free full text ↗

Source: The efficacy and safety of thymosin Î±1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Further reading · 4 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

Thymosin alpha-1. ↗
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2001 May 15 · Journal Article, Review

Aging and Thymosin Alpha-1. ↗
International journal of molecular sciences · 2025 Nov 27 · Journal Article, Review
Read available full text ↗

beta-Thymosins. ↗
Annals of the New York Academy of Sciences · 2007 Sep · Journal Article, Research Support, Non-U.S. Gov't, Review

Thymosin alpha-1 treatment in chronic hepatitis B. ↗
Expert opinion on biological therapy · 2015 · Editorial, Research Support, Non-U.S. Gov't

Repeat this PubMed search ↗

Search additional PubMed records ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Safety & precautions

Safety evidence & remaining uncertainty

FDA considers compounded-product safety information inadequate. Trial tolerability in critically ill patients does not establish suitability for routine wellness use.

Source: FDA · Peptide compounding safety concerns ↗

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

What are people discussing?

No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.

Watch the source discussions

9 matching video records · 5 with captions indexed.

Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.